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Abstract
Insulin resistance (IR) precedes the development of type 2 diabetes (T2D) and increases
cardiovascular disease risk. Although genome wide association studies (GWAS) have
uncovered new loci associated with T2D, their contribution to explain the mechanisms lead-
ing to decreased insulin sensitivity has been very limited. Thus, new approaches are neces-
sary to explore the genetic architecture of insulin resistance. To that end, we generated an
iPSC library across the spectrum of insulin sensitivity in humans. RNA-seq based analysis
of 310 induced pluripotent stem cell (iPSC) clones derived from 100 individuals allowed us
to identify differentially expressed genes between insulin resistant and sensitive iPSC lines.
Analysis of the co-expression architecture uncovered several insulin sensitivity-relevant
gene sub-networks, and predictive network modeling identified a set of key driver genes that
regulate these co-expression modules. Functional validation in human adipocytes and skel-
etal muscle cells (SKMCs) confirmed the relevance of the key driver candidate genes for
insulin responsiveness.
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Author summary
Insulin resistance is characterized by a defective response (“resistance”) to normal insulin
concentrations to uptake the glucose present in the blood, and is the underlying condition
that leads to type 2 diabetes (T2D) and increases the risk of cardiovascular disease. It is
estimated that 25–33% of the US population are insulin resistant enough to be at risk of
serious clinical consequences. For more than a decade, large population studies have tried
to discover the genes that participate in the development of insulin resistance, but without
much success. It is now increasingly clear that the complex genetic nature of insulin resis-
tance requires novel approaches centered in patient specific cellular models. To fill this
gap, we have generated an induced pluripotent stem cell (iPSC) library from individuals
with accurate measurements of insulin sensitivity, and performed gene expression and
key driver analyses. Our work demonstrates that iPSCs can be used as a revolutionary
technology to model insulin resistance and to discover key genetic drivers. Moreover,
they can develop our basic knowledge of the disease, and are ultimately expected to
increase the therapeutic targets to treat insulin resistance and type 2 diabetes.
Introduction
Insulin resistance is necessary for the development of the metabolic syndrome and type 2 dia-
betes (T2D), and is a major risk factor for cardiovascular disease [1], which together represent
a modern pandemic. While genome-wide association studies (GWAS) have identified a large
number of genomic loci associated with T2D-related traits, most of these signals are associated
with pancreatic β-cell function and insulin secretion rather than with insulin resistance [2].
While a few insulin resistance genes have been identified [3–6], the underlying genetic archi-
tecture of insulin resistance remains unknown.
To fill this gap, we sought to take advantage of a large library of induced pluripotent stem
cells (iPSCs) derived from individuals across the spectrum of insulin sensitivity who have also
undergone GWAS genotyping [7,8]. We have fully characterized these iPSC lines and demon-
strated determinants of iPSC transcriptional variability. For instance, we found that the highest
across individual contribution to variability in our cohort was enriched for metabolic func-
tions [9].
These results prompted us to more specifically analyze the gene expression patterns and
networks associated with the insulin sensitivity status of the iPSC donors. For complex condi-
tions like insulin resistance with polygenic susceptibility, systems biology and network model-
ing, integrating multiscale-omics data like genetic and transcriptomic data, provide a useful
context in which to interpret associations between genes and functional variation or disease
states [9–13]. Therefore, the reconstruction of molecular networks can lead to a more system-
atic and data driven characterization of pathways underlying disease, and consequently, a
more comprehensive approach to identifying and prioritizing therapeutic targets [12,13].
Recent advances in co-expression and causal/predictive network modeling [9,11,12,14] allow
us to take such an approach. The work described here links complex disease phenotypes from
highly characterized subjects to concomitant molecular networks that can then be used to
uncover coherent, functional molecular sub-networks and their key driver genes that ulti-
mately determine the clinical phenotypes.
In summary, we performed differential expression analyses between insulin resistant (IR)
and insulin sensitive (IS) iPSCs, built co-expression networks to systematically organize the
data into coherent modules enriched for insulin sensitivity associated functions and
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implemented key driver analyses to identify genes that control and regulate critical aspects of
the IR and IS networks. Finally, we empirically validated the constructed networks in iPSCs
and the prioritized key drivers through insulin responsiveness associated functional assays in
human adipocytes and skeletal muscle cells (SKMCs)(Fig 1).
Results
Insulin sensitivity measurement and iPSC generation
Individuals in the study have accompanying genome-wide genotyping and gold standard mea-
surement of insulin sensitivity (i.e. steady state plasma glucose-SSPG-derived from an insulin
suppression test). Other biometric parameters include age, body mass index, sex and race/eth-
nicity (S1 Table). We generated three to seven iPSC lines from each individual, with no appar-
ent differences in the reprogramming efficiency between IR and IS cells (S1A Fig). The
complete pipeline for iPSC generation and quality control has been previously described [9].
Briefly, we generated RNA-seq data for 317 iPSC lines from 101 individuals and, after quality
control [9], we analyzed RNA-seq data from 310 samples from 100 individuals, of which 48
were IS (149 samples) and 52 were IR (161 samples). The SSPG cut-off to discriminate between
IR or IS state was set at 140 mg/dl based on previous publications [15–17] (S1B Fig). The aver-
age SSPG values were 84 mg/dl for the IS group and 210 mg/dl for the IR group. Finally, sam-
ples in both groups were age and body mass index (BMI) matched to avoid possible biases
(mean age 57.7 years old and 59.5 in the IS vs. IR group, respectively, and mean BMI 28.5 in
the IS vs. 30 in the IR group).
Differential expression analysis
iPSC lines have been demonstrated to recapitulate many Mendelian diseases, including insulin
resistance resulting from severe mutations in the insulin receptor [18,19]. However, the extent
to which iPSCs are a valid model for the study of common polygenic forms of IR/T2D is still
unknown. To test the hypothesis that iPSCs maintain at least some differential characteristics
based on the insulin sensitivity status of the individual they were derived from, we sought to
analyze the differential expression (DE) signature between IR and IS iPSC lines. To that end,
after alignment and feature counting, RNA-seq counts were normalized and residual expres-
sion was computed after adjusting for both technical (sequencing batch, RNA extraction
method; modeled as random effects) and biological/population (reprogramming source cell,
sex, ethnicity, age, BMI; modeled as fixed effects) covariates (Figs 1 and S2).
We generated several iPSC lines per individual and thus, the effective sample size of our
analyses is the number of patients, not the number of samples. However, since insulin resis-
tance status is an individual-level characteristic, we could not adjust for donor without remov-
ing the signal of interest (insulin sensitivity status). Therefore, we analyzed the data in two
ways. First, we used all samples (referred to as the AS analysis) without accounting for multiple
clones for each individual. Second, we averaged the residual expression levels for all clones of
each individual (referred to as the average-per-patient, ApP, analysis). While generalized esti-
mating equations, mixed models or similar techniques can be used to compute residual expres-
sion levels taking into account the correlation of samples from the same individuals, these
approaches will not allow constructing co-expression and predictive networks for data with
multiple clones per individual. We therefore decided to use both the AS and ApP approaches,
thereby consistently using the same residual expression levels in all analyses. Importantly,
iPSC lines from the same individual cluster together (S3 Fig) and samples from IR donors
tend to cluster together as do samples from IS donors, whereas this is not the case according to
sex (Fig 2).
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We identified 1,338 differentially expressed genes between IR and IS samples in the AS analysis
(FDR adjusted p-value< 0.05) whereas in the ApP analysis no significantly differentially
expressed genes were identified (S2 Table). However, the comparison of the rank of the test statis-
tics for the 500 most differentially expressed genes from both analyses shows consistent results,
with very similar ranks for AS and ApP DE analysis (Spearman correlation coefficient = 0.66,
median rank in both AS and ApP = 308, paired Wilcoxon signed-rank test P = 0.90) (Fig 2). This
result suggests that the lack of statistically significant DE genes in the ApP analysis is due to the
reduced sample size. We also performed sensitivity analyses: a) blocking by patient ID, 947 of the
top 1338 most differentially expressed genes were shared with AS residuals (71% overlap) and b)
using SSPG as a continuous score instead of performing an IR vs IS dichotomization showed that
840 of the top 1338 DE genes with this approach were overlapping with AS residual DE gene list
(63%). As our holistic approach to compare IR and IS states was based and scaled to the entire
transcriptional network, we used differential expression analysis to leverage our key driver
analysis.
Co-expression network analysis
We trained four co-expression networks (Fig 3A–3D) [14,20]: for each of the AS and ApP
adjusted expression residuals, we built one network for IR samples and another one for IS
Fig 1. Flowchart detailing the individual steps of the integrative predictive network modeling analysis pipeline
and functional molecular validation: sample collection, data generation, data normalization, differential
expression analysis, co-expression networks, predictive networks and key driver analysis, prioritization of KDs
and molecular and functional validation.
https://doi.org/10.1371/journal.pcbi.1008491.g001
Fig 2. Differential expression analysis. (a) All-Samples (AS): 1338 differentially expressed genes with multiple testing corrected p-value<0.05 are shown. (b)
Average-per-Patient (ApP): top 500 differentially expressed genes identified in ApP are shown. Color scale indicates normalized residual expression levels (blue: low
expression, orange: high expression). Columns have been arranged according to clustering of the samples / donors, (purple: insulin resistant, turquoise: insulin
sensitive, orange: female, grey: male). Clustering was performed on all samples / donors agnostically of their IR / IS status and sex.
https://doi.org/10.1371/journal.pcbi.1008491.g002
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samples. Co-expression networks identify groups of genes (modules) with highly correlated
expression patterns across samples, indicating that they are involved in similar biological pro-
cesses. We used gene set enrichment analysis (GSEA) [21,22] and the gene ontology (GO, C5
biological processes, v5.1)[23,24] gene sets from the Molecular Signatures Database (MSigDB)
[21] to test the modules of each co-expression network for enrichment in insulin or metabo-
lism related pathways. Specifically, we identified 5 relevant modules in the AS IR network (cor-
responding to a total of 1,565 genes) -reflecting glucose, lipid and cholesterol metabolic
processes and mitochondrial function pathways-, 3 in the AS IS network (430 genes)–glycoly-
sis, cholesterol biosynthesis and electron transport chain-, 4 in the ApP IR network (1,689
genes)–glucose metabolic process, lipid and cholesterol associated processes and regulation of
cellular localization-, and 5 in the ApP IS network (2,791 genes)–hexose metabolic process,
respiratory electron transport chain, cholesterol, lipid and small molecule biosynthesis-(Fig
3E–3H). To evaluate the significance of correlations between gene pairs in the co-expression
network modules, we permuted the AS and ApP residuals 10 times and computed the correla-
tion between all pairs of genes in each module per co-expression network (AS IR, AS IS, ApP
IR, ApP IS). The correlations from the permuted data formed a background distribution to
calculate the p-values of the actual co-expressed gene pairs, which showed that the majority of
the pairwise correlations between genes were significant in two or more modules for each of
the four networks (S4 Fig).
Predictive networks
Seeding genes for each predictive network were obtained by expanding the set of genes in the
selected modules from the corresponding co-expression network by including all genes con-
nected to any of the selected module genes in k = 3 or fewer steps in a prior, cell type-specific
network derived from public gene and protein interaction databases: ConsensusPathDB
(CPDB) [25] and MetaCore (v6.24 from Thomson Reuters). The above seeding gene selection
process ensures that genes impacting insulin sensitivity are included, while reducing the fea-
ture space by excluding irrelevant genes to train the predictive network. Our final seeding gene
sets consisted of 7,250 (AS IR), 3,797 (AS IS), 8,183 (ApP IR) and 9,712 (ApP IS) genes respec-
tively. This final seeding gene list was used in the top-down and bottom-up predictive network
pipeline (see Material and methods section) to build causal network models.
Key driver analysis (KDA) and ranking
KDA requires a starting set of genes to be analyzed and we ran the KDA multiple times, once
for the genes in each co-expression module that was enriched for metabolic pathways, as well
as for the DE genes from the AS and ApP analyses (5% FDR for AS and the top 500 DE genes
for ApP). Consequently, for each network a given gene can be identified as a KD based on the
co-expression modules and/or the DE genes, and the more often a gene is identified as KD
Fig 3. The topological overlap matrix (TOM) indicating co-expression between genes and their corresponding
pathway enrichment analysis of the IR and IS co-expression network in AS and ApP. The color bars on top and to
the left of each TOM indicate different co-expression modules (WGCNA labels co-expression modules according to a
sequence of colours; each colour corresponds to a different module with no further meaning of the colour labels). Only
genes included in co-expression modules are shown. The color scales for the different TOMs depend on the soft power
parameter used by WGCNA and hence we have not provided color scales for these heatmaps; the main point of the
TOM is to show the connections (i.e. co-expression) between blocks (i.e. modules) of genes. Each module of co-
expressed genes will correspond to different biological functions and thus an annotation of the modules will allow us to
select modules to seed the predictive networks. (a) TOM of IR in AS; (b) TOM of IS in AS; (c) TOM of IR in ApP; (d)
TOM of IS in ApP. (e)-(h) Pathway enrichment analysis results for selected modules from each co-expression
networks in (a)-(d).
https://doi.org/10.1371/journal.pcbi.1008491.g003
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across networks, the stronger the evidence it is implicated in the phenotype. Based on this
approach, we performed KDA [26] on the four predictive networks and identified, a total of
231 key drivers (KD) in the AS predictive networks and 237 key drivers in the ApP networks.
There were 45 key driver genes common to both sets (S4 Table). We selected the KDs for fur-
ther study based on the number of appearances across networks, which rendered 9 genes
(BNIP3, CARS, IDH1, NDUFB1, HMGCR, HPN, FDPS, SLC27A1, TMEM54) that are KDs 3 or
more times in the AS and ApP networks (Fig 4A and S4 Table).
For these top 9 KDs, we further looked at the topology of the local sub-networks around each
of them in the four networks and represented the incoming source: selected module genes, DE
genes, or expanded genes through pathFinder (Figs 4B and S5). The specific module each gene
originates from and the enriched functions for those modules can be found in S6 Fig and S3
Table. In addition, we computed 2 scores (Table 1): the sum of the inverse path lengths (i.e. if a
gene is k steps down/up-stream of another gene, then the inverse path length is 1/k) from each
key driver to the significantly differentially expressed genes in the AS networks and the top 500
most differentially expressed genes in the ApP network (DE proximity score) and second, the
difference between the sums of the inverse path lengths from each KD to other KDs downstream
Fig 4. Predictive Causal Network (PCN), key drivers and sub-networks of the tested key drivers. (a) key driver replication across networks. For each network a given
gene can be identified as a KD based on the co-expression modules and/or the DE genes, and the more often a gene is identified as KD across networks, the stronger the
evidence it is implicated in the phenotype; (b) sub-networks of top 9 key drivers for IR AS (left) and IS AS (right). We highlight the key drivers (red triangles) and the 2
step downstream genes. Genes from selected modules (blue), DE genes (orange) and expanded genes through pathFinder (grey).
https://doi.org/10.1371/journal.pcbi.1008491.g004
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of them and the inverse path lengths to other KDs upstream of them (KD dominance score).
The higher the DE proximity score, the more there are paths from this KD to DE genes and/or
the shorter these paths are; the higher the KD dominance score, the more other KDs are more
directly downstream of this KD and/or the fewer other KDs are directly upstream of it.
Finally, we performed a directed literature search combining the different KDs with the
terms insulin, glucose, and diabetes. The results of the relevant publications associating the
KDs to insulin sensitivity are summarized in Table 1. Briefly, both BNIP3 and SLC27A1 have
been strongly associated with insulin resistance phenotypes. Solute Carrier Family 27 Member
1 (SLC27A1, also known as FATP1) is an insulin-sensitive fatty acid transporter involved in
diet-induced obesity and has been associated to IR in skeletal muscle [27,28] and BCL2/Ade-
novirus E1B 19kDa Interacting Protein 3 (BNIP3) is essential for mitochondrial bioenergetics
during adipocyte remodeling [29], regulates mitochondrial function and lipid metabolism in
the liver [30] and in conjunction with PPARγ couples mitochondrial fusion-fission balance to
systemic insulin sensitivity [31]. Although informative about the quality of our KDA, the body
of publications related to these two KDs decreased the interest on further validation. Among
the remaining top KDs, HMGCR and FDPS have the highest combined DE proximity and KD
dominance scores and both genes participate, together with squalene epoxidase (SQLE)-
another KD that appears in both AS and ApP networks (S4 Table)- in the cholesterol biosyn-
thesis pathway. Given, i) the high DE proximity and KD dominance scores, ii) the shared met-
abolic pathway, iii) the widespread use of statins (HMGCR inhibitors) as therapeutic drugs to
lower cholesterol levels in patients with high LDL-cholesterol, and iv) the emerging role of
HMGCR in energy balance, metabolism and diabetes risk [32–35], we sought to validate our
KDA, both transcriptionally and functionally, focusing on HMGCR, FDPS and SQLE.
Network validation
We validated the causal IR/IS networks and the key driver analysis using the DE gene signature
from an HMGCR inhibition experiment in iPSC cell lines derived from both IR (n = 6) and IS
individuals (n = 6). For each iPSC line in this experiment (S5 Table) we generated RNA-seq
data in presence or absence of atorvastatin, an HMGCR inhibitor (statin) widely used in
patients with hypercholesterolemia [36]. Previous efforts have validated predictive networks
through similar approaches [12,37]
The comparison of atorvastatin-treated and untreated samples resulted in a list of 3205 DE
genes (S6 Table) that showed the highest enrichment for statin action pathway and cholesterol
Table 1. Summary statistics and references for the top ranked key drivers. Network appearances: number of appearances across IR and IS networks for AS and ApP
DE proximity: sum of the inverse path lengths from each key driver to the significantly differentially expressed genes in the AS networks and the top 500 most differentially
expressed genes in the ApP network. KD dominance: the difference between the sums of the inverse path lengths from each KD to other KDs downstream of them and the
inverse path lengths to other KDs upstream of them. KD: key driver.
KD GENE Network appearances DE proximity KD dominance REFS.
BNIP3 BCL2/Adenovirus E1B 19kDa Interacting Protein 3 4 20.30 0.00 [29–31]
FDPS Farnesyl Diphosphate Synthase 3 16.22 1.42 none
SLC27A1 Solute Carrier Family 27 Member 1 3 10.85 0.25 [27,28]
HMGCR 3-Hydroxy-3-Methylglutaryl-CoA Reductase 3 10.15 0.58 [34,38,44–46,49]
CARS Cysteinyl-TRNA Synthetase 3 7.80 0.00 none
TMEM54 Transmembrane Protein 54 3 7.57 1.00 none
IDH1 Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic 3 7.32 -3.25 [85–88]
HPN Hepsin 3 6.67 0.00 none
NDUFB1 NADH:Ubiquinone Oxidoreductase Subunit B1 3 6.45 0.00 none
https://doi.org/10.1371/journal.pcbi.1008491.t001
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biosynthetic pathway and other related pathways (S7 Table), suggesting that HMGCR inhibi-
tion triggers a transcriptional compensatory response to balance the decrease in the cholesterol
pathway intermediates.
Next, we wanted to compare the specific responses of IR vs. IS iPSCs to atorvastatin treat-
ment. When considering IR or IS groups independently, the number of DE genes was reduced
to 785 (IR) and 711 (IS) (S6 Table). Surprisingly the DE genes between IR and IS samples are
just partially overlapping (343/785 or 343/711, respectively) (Fig 5A) which suggests a differ-
ential response to atorvastatin treatment based on the IR/IS status of the donors. Moreover,
pathway enrichment analysis (S7 Table) for the 442 IR-specific and 367 IS-specific DE genes
demonstrated striking differences in the enriched pathways between IR and IS iPSCs (Fig 5B),
which could be related to the disproportionate incidence of T2D in insulin resistant patients
under statin treatment [38]. Although atorvastatin treatment translates the perturbation of a
metabolic pathway into measurable transcriptional changes and gives clues about HMGCR
functionality and its association to insulin sensitivity, it requires of novel additional analyses to
validate the predictive network.
To validate our network structure, i) we calculated the percentage of genes in each down-
stream layer of HMGCR in the network that are significantly altered (FDR<0.05) in gene
expression in HMGCR inhibition experiment. We found that for both IR and IS networks
more than 80% of the genes in the first layer downstream of HMGCR are DE genes and that
this percentage decreases as the distance to HMGCR increases in the network (Fig 6A); ii) we
also compared DE gene fold-changes (log FC) (Fig 6B) and associated significance (-logFDR)
(Fig 6C) to the AS network topology. Among the genes located downstream of HMGCR in
both the IR and IS networks, the fold change and their significance decrease as the distance to
Fig 5. Differential pathway enrichment after HMGCR inhibition in IR vs IS iPSCs. (a) Venn diagram for the IR-specific (442 genes), IS-specific (367 genes) and IR/IS
overlapping (343 genes) DE genes due to HMGCR inhibition. (b) Pathway enrichments for the groups defined in (a). Top-10 significant pathways are shown for each
group (full list of pathway enrichment can be found in S7 Table).
https://doi.org/10.1371/journal.pcbi.1008491.g005
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HMGCR increases (Fig 6B and 6C). The same pattern was observed in the ApP network (S7
Fig). Finally, all four predictive networks (AS IR, AS IS, ApP IR and ApP IS) show a significant
enrichment downstream of HMGCR for DE genes due to HMGCR inhibition (S8 Table).
Thus, our results confirmed that percentage of DE genes, DE gene fold change and associ-
ated significance decreases as the distance (number of layer/steps away) from the perturbed
target increases, and that DE genes are enriched in the downstream steps of HMGCR com-
pared to non-DE genes. Taken together, the HMGCR-inhibition experiment validated the pre-
dictive networks and their topological structure.
Functional validation
We next sought to functionally validate the prioritized KDs -HMGCR, FDPS and SQLE- in
processes associated with insulin sensitivity and in particular, to insulin mediated glucose
uptake in relevant metabolic cell types such as adipocytes and SKMCs. To that end, we differ-
entiated the Simpson-Golabi-Behmel syndrome (SGBS) human preadipocyte line [39] and the
human SKMC line HMCL-7304 [40] to terminally differentiated adipocytes and myotubes,
respectively. We focused our validation efforts on HMGCR, FDPS and SQLE as these three key
drivers participate in the same metabolic pathway-cholesterol biosynthesis- and, in addition,
Fig 6. Predictive Network Validation (AS network) by RNA-seq data in Atorvastatin treated iPSC lines. (a) The percentage of DE genes decreases as the distance
(layers) from HMGCR increases. (b) Among the genes located downstream of HMGCR, the fold change decreases as the distance to HMGCR increases. (c) The p-value of
differential expression analysis from Atorvastatin experiment decreases along the steps down from HMGCR. Upper lane: AS IR network. Lower lane: AS IS network.
https://doi.org/10.1371/journal.pcbi.1008491.g006
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statins (HMGCR inhibitors] are at the center of an intense debate about their effect on insulin
resistance and type II diabetes risk [33,41–45].
To functionally inhibit the three candidate genes, we used well-described and widely used
chemical inhibitors: atorvastatin (targeting HMGCR), alendronate (for FDPS) and terbinafine
(for SQLE) (S8 Fig). As shown in Fig 7A, all three inhibitors decrease insulin mediated glucose
uptake in human adipocytes. However, only HMGCR inhibition demonstrates a detectable
decrease of preadipocyte growth and differentiation efficiency (Fig 7B and 7C). Along the
same lines, atorvastatin inhibits both insulin mediated glucose uptake and cell proliferation in
Fig 7. Functional validation of key driver genes. (a) Insulin mediated glucose uptake assay in mature human adipocytes. Fold change values are shown with
respect to no insulin (-). Each panel shows the effect of varying concentrations of inhibitor for HMGCR (atorvastatin), FDPS (alendronate) and SQLE
(terbinafine). (b) Adipogenic differentiation assay. The effect of different concentrations of the inhibitors over SGBS adipogenesis is measured by absorbance
measurement of Oil-O-Red emission at 500nM. (c) Growth assay in human SGBS preadipocytes. Crystal violet staining after 12 days of assay in presence/
absence of the inhibitors. (d) Insulin mediated glucose uptake assay in mature human SKMCs. See (a). (e) Growth assay in human SKMCs. See (b). Results
represent mean±SD, and statistical significance was evaluated through One way ANOVA �p<0.05, ��p<0.01, ���p<0.001 compared to insulin condition
without inhibitors (a and d) or basal differentiation (c).
https://doi.org/10.1371/journal.pcbi.1008491.g007
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SKMCs, while alendronate and terbinafine show only a significant effect on glucose uptake
(Fig 7D and 7E).
Our results suggest that data driven co-expression and predictive networks combined with
key driver analyses are powerful tools for the discovery of novel genes involved in IR.
Discussion
Although GWAS studies have targeted T2D and insulin resistance- associated glycemic traits,
the success in identifying new genes that contribute to insulin resistance risk has been fairly
limited. Our group has previously demonstrated that GWAS studies based on gold-standard
measurements allows the discovery of novel genes associated with insulin resistance [6] but
the power to detect novel loci associated to IR has been limited by sample size. In addition, the
genetic complexity and multicellular targets of insulin resistance advocate for the development
of new cellular systems and holistic genetic approaches.
With this goal in mind, we generated an iPSC library with accurate measurements of insu-
lin sensitivity that reflects the broad spectrum of insulin responses in human populations.
Given our limited sample size (52 IR vs. 48 IS individuals for a total of approximately 300 iPSC
lines), and to overcome the limitations of the traditional DE analyses, we developed a more
holistic view of the genetic networks associated to IR through the construction of co-expres-
sion networks for both IR and IS iPSC lines. In addition, for network construction we per-
formed a dual approach where we used the gene expression values for all samples (AS)(to
increase power) or the average per patient (ApP) (to increase stringency). One limitation of
our study is that given the complex polygenic nature of insulin sensitivity and given the com-
plexity of the generated data and the multiple sources of variance to gene expression, the mul-
tiple corrections that were needed to perform the DE analyses could potentially mask some of
the genetic signals associated to insulin sensitivity. Moreover, the extent to which different DE
analyses, like using SSPG as a continuous variable instead of dichotomizing IR and IS status,
would affect network construction has not been explored in the present study. However, the
constructed networks highlighted co-expression modules enriched for cellular functions like
respiratory electron transport chain, glycolysis, cholesterol and steroid biosynthesis and glu-
cose metabolism that are intimately associated with insulin sensitivity-associated processes.
We performed predictive network and key driver analyses to investigate the central genetic
nodes that control the aforementioned modules and functions and thus, are most likely to be
involved in the etiology of insulin resistance.
To better delimit and rank our key driver list we considered only the KDs defined as such
in both AS and ApP approaches (45 genes) and then we considered the total number of
appearances in the 4 constructed networks (AS IR, AS IS, ApP IR and ApP IS), which identi-
fied 9 top key drivers. As highlighted in Table 1, IDH1, BNIP3 and SLC27A1 (FATP-1) have
been shown to participate in functions associated with insulin sensitivity or have been directly
associated to insulin resistance or type 2 diabetes. Among the rest of the selected key drivers,
the top two key drivers with the highest DE path and KD path values, which represents the
connectivity of a given KD to DE genes and to other KDs, are Farnesyl Diphosphate Synthase
(FDPS) and 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR) which coordinately par-
ticipate in the cholesterol biosynthetic pathway. Moreover, another gene participating in this
pathway, SQLE is among the 45 KDs shared between both approaches. Meta-analysis of clini-
cal trials with statins (HMGCR inhibitors) have shown an increase in T2D incidence [44–46],
which seems to be dose related [35,43] and that affects insulin resistant individuals in a dispro-
portionate way [38]. In addition, alleles in HMGCR that lower LDL-C confer an increased risk
of developing T2D and individuals with familial hypercholesterolemia are protected against
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T2D [34,47], leading to speculation that statins affect insulin sensitivity and insulin secretion
[45,48], although the exact cellular and molecular mechanisms to such an increase in T2D risk
are still not well understood.
The predictive network not only illustrates co-regulated genes in the same pathway but can
also demonstrates causality upstream and downstream of a given gene. There have been suc-
cessful efforts to validate predictive networks [12,37], and therefore, it was critical to show that
we could capture the downstream effector genes of key drivers in the predictive networks. Our
empirical network validation through HMGCR inhibition demonstrated enrichment for DE
genes and log fold change in the downstream proximity of HMGCR, which validates the overall
structure of the network. In addition, we observed a differential response to atorvastatin treat-
ment depending the IR or IS state of the iPSC tested, which could be related to the increased
incidence of T2D under statin treatment that seems to specially affect IR individuals [34,38,41].
Our functional validation assays in human preadipocyte (SGBS) cells demonstrate that
HMGCR inhibition decreases preadipocyte proliferation, and differentiation and insulin
mediated glucose uptake in mature adipocytes, similar to previous results in mouse preadipo-
cyte lines [49–51]. In addition, both proliferation and insulin mediated glucose uptake are
affected in the human SKMCs (HMCL-7304), treated with atorvastatin. FDPS and SQLE inhi-
bition have also a significant effect decreasing insulin mediated glucose uptake in human adi-
pocytes and myotubes, while not affecting proliferation or differentiation. These results
suggest that the effects on proliferation and differentiation of adipocytes and SKMCs are inde-
pendent of the disturbance in insulin mediated glucose uptake. In addition, SQLE inhibition
exerts a comparable effect on insulin mediated glucose uptake when compared to HMGCR
inhibition, which suggests that the underlying mechanisms could be mediated by the deregula-
tion of intracellular or membrane bound cholesterol levels [32,52]. Other proposed mecha-
nisms to affect insulin facilitated glucose uptake include decreased expression levels of SLC2A4
(GLUT-4) and caveolin-1 [51,53], disturbed RHOA and RAB4 signaling lowering GLUT-4 lev-
els in the plasma membrane [54,55], perturbation of the insulin signaling pathway [55,56] and
accumulation of free fatty acids [49,57]. Although our results suggest that the cholesterol bio-
synthetic pathway is directly involved in the insulin-mediated glucose uptake impairment
induced by atorvastatin, it is highly probable that additional mechanisms are participating. In
addition, different types of statins could exert differential effects in a concentration, species
(mouse vs. human) or cell specific context (adipocytes vs. skeletal muscle cells). In any case,
further studies are necessary to dissect the specific mechanisms by which statins increase the
risk of developing T2D.
In summary, our work suggests that: i) iPSC retain a donor-specific signature [9], ii) co-
expression and predictive networks combined with key driver analyses uncovered robust can-
didates to participate in IR, iii) IR iPSCs have a differential response to HMGCR inhibition
when compared with IS cells and iv) the cholesterol biosynthetic pathway is involved in the
insulin-mediated glucose uptake impairment observed in human adipocytes and SKMCs.
Taken together, these results suggest that iPSCs technology will offer a novel and sophisticated
model for the study of IR and the associated cardiovascular disease, especially when relevant
metabolic (adipocytes or SKMCs) and vascular (endothelium) cell types are generated from
our iPSC library with accurate measurements of insulin sensitivity.
Material and methods
Ethics statement
The study included 201 subjects who had volunteered for prior studies between October 2002
and October 2013 and were in general good health. The individuals were re-contacted and re-
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consented for this study. Stanford Institutional Review Board approved the study protocol,
and all subjects gave written informed consent for study participation.
Patient recruitment, biological parameters and insulin sensitivity
measurement
Patient recruitment and blood sampling were performed as previously described [9]. Insulin
sensitivity measurement was perf ormed by a modified insulin suppression test in accordance
with Knowles et al.[7] See S1 Table for complete demographic data.
RNA-Seq processing
STAR v2.4.0g1 [58] was used to align RNA-seq reads to the human genome built GRCh37.
Using featureCounts v1.4.4 [59], we counted the uniquely mapping reads overlapping genes as
annotated by ENSEMBL v70.
Statistical analyses and data processing
Unless otherwise specified, statistical analyses and data processing steps were done using R
v3.0.3 [60]. Code for the various analyses described below has been published on GitHub
(https://github.com/gitMarcH/iPSCsInsulinResistance and https://github.com/zhukuixi/KDA).
Expression data normalization and covariate adjustment
After filtering out lowly expressed genes (at least 1 counts-per-million (CPM) in 30% or more
of samples), we have data for 15,294 genes left for analysis. We used the R packages edgeR [61]
and limma [62] to normalize the RNA-seq expression data. The edgeR function calcNormFac-
tors() is used to compute TMM [63] weights which are applied using the limma function voom
(). The final normalized expression values that are output by voom() are on the log2 counts-
per-million (CPM) scale.
All RNA-seq data analyses were performed on expression residuals corrected for the effects
of technical (sequencing batches and RNA preparation kits, reprogramming source cell) and
patient covariates (sex, ethnicity, age, BMI) in line with existing differential expression analysis
literature [64–66]. Batch and RNA preparation kit were adjusted for as random effects using
the variancePartition R library [67] whereas reprogramming source cell, and patient character-
istics were adjusted for as fixed effects using the limma [60] package. Each of the variables we
adjusted for corresponds to technical or biological variation that will mask independent
genetic signals of insulin sensitivity. At the same time each of these variables impacts the
expression levels of a significant number of genes, and hence, any differences in these factors
between the IR/IS groups are likely to confound the biological variation due to IR. The vari-
ance partition analysis in S2 Fig provides insights into the gene expression variability corre-
lated with these covariates.
As detailed in the results section, due to having multiple clones per patient, we computed
two sets of expression residuals: one (AS) using all samples from all clones for every patient
and one (ApP) where we averaged residuals per patient.
Genomic data and expression quantitative trait (eQTL) analysis
We have described these processing and analysis steps previously [9]: “Genotype data were fil-
tered to remove markers with over 5% missing entries, minor allele frequency below 1% and
Hardy-Weinberg p value < 10−6. Genotypes were phased with SHAPEIT v2.r790 [67], and
missing genotypes were imputed with Impute2 v2.3.2 [68] using the reference panel from the
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1000 Genomes Project Phase 3 [69]. Markers with high imputation quality (INFO > 0.5;[68]
and minor allele frequency over 1% were retained for downstream analyses.
Following standard practice, only individuals of European ancestry were included in the
eQTL analysis in order to avoid false positives due to the correlation between ancestry and
gene expression. Principal components analysis based on genome-wide genotype data identi-
fied 81 individuals of European ancestry for eQTL analysis. eQTL analysis was performed with
MatrixEQTL v2.1.1 [70] using the first 5 genotype principal components as covariates. Latent
variables were identified in the gene expression data using PEER v1.0 [71]. [. . .]. Cis-eQTL
analysis considered markers within 1Mb of the transcription state site of each gene. False dis-
covery rates were computed following Benjamini–Hochberg.” The purpose of the cis-eQTL
analysis in this work was to have structural priors for the predictive networks (see “Predictive
networks” section below).
Differential expression analysis
For the expression residuals used for the co-expression and predictive network analyses we
adopted 2 analysis streams: one where we use all samples without adjusting for patient ID (AS)
and one where we average residuals per patient (ApP). Differentially expressed genes were
determined using a linear model, as implemented in the lmFit function from the limma pack-
age v3.18.13 in R. Statistical significance was assessed using a cut-off of 0.05 on FDR adjusted
p-values.
Co-expression networks and selection of co-expression modules
We constructed co-expression networks using the coexpp R package [20], which provides an
optimized workflow for the WGCNA [14] R package (v1.14–1 used here together with R
v3.0.3) for large numbers of genes. The soft threshold powers used for the AS IR, IS and ApP
IR, IS co-expression networks were 7.5, 9.0, 7.5 and 9.5 respectively. These were chosen by the
pickSoftThreshold() function from the WGCNA package with an R2 cut-off of 0.8, unless
visual inspection of the R2 curve as a function of power revealed a plateau near 0.8 and a lower
power achieved an R2 of almost 0.8 (e.g. between 0.78 and 0.8). In this case, that lower power
was chosen instead. All 15,294 genes that passed the low-expression threshold were used to
build the co-expression networks. Seeding genes for the predictive network (specifically, the
input to pathFinder) were selected to be the genes in co-expression network modules statisti-
cally enriched (FDR < 0.05) for GO terms relevant to insulin resistance related traits (biologi-
cal processes only).
Predictive networks
Bayesian networks (BN), which provides a natural framework for capturing causality among
highly dissimilar types of data, stochastic processes of biology systems, and noise, have become
increasingly popular for modeling biology systems [72–75] due to their inherent capability to
integrate multi-scale ‘omics’ data such as genetic context, transcriptomics, proteomics, meta-
bolomics, epigenomics and literature knowledge. While Bayesian networks are useful in deci-
phering causality of molecular interactions, one fundamental problem is that BN can NOT
infer causality among statistically equivalent structures, i.e. multiple network structures with
opposite causality direction fit equally well to the data. The problem of partial causality in BN
has limited their effectiveness in identifying high-quality key drivers by inducing randomness
to the causality of learned structure.
Recently, we developed the top-down and bottom-up predictive network pipeline to build
causal predictive network models [76], which leverages the bottom-up belief propagation
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engine [77,78] as a sub-routine to infer causality among equivalent structures. Biochemical
reactions can be modeled as nonlinear perturb-response relations, e.g. hyperbolic response,
sigmoidal graded/switched response, rise/fall pulsed response, complex non-monotonic or
periodical oscillation [79]. The bottom-up method leverages the nonlinearity of biochemical
reactions to infer causality of a molecular interaction, i.e. fitting better to the data along true
causal direction than false causal direction, therefore, breaks the statistical equivalence. By
integrating the novel bottom-up causality inference approach with (top-down) Bayesian net-
works, the integrated top-down & bottom-up predictive network platform will result in com-
plete causal network with discerned causality among equivalent structures. This pipeline
inherits the advantage of BN in integrating the multi-scale ‘omics-’ data (genetics, genomics,
proteomics, metabolomics, epigenomics) to construct multi-scale network models. Conse-
quently, the nodes in a predictive network can represent any variable of interest within the bio-
logical system, e.g. levels of gene expression [9,76,80] the genotype of a locus [9], the activity of
a protein [76], or the abundance of a metabolite, to name just a few. In addition, the predictive
network inherited the capability to predict new molecular phenotype upon genetic perturba-
tions through its internal bottom-up belief propagation engine [77,78]. Also, the genotype data
is incorporated as cis-eQTL genes in the model where they are constrained to be the top node
(without other parents). As cis-eQTLs causally affect the expression levels of neighboring
genes, they can serve as a source of systematic perturbation to infer causal relationships among
genes [9,81,82]. Consequently, we incorporated cis-eQTL genes into each network as structural
priors. We used the genes in the selected modules from co-expression networks as seeding
genes for predictive network modeling.
To build a predictive network, our platform involves the following steps: i) Evaluate the var-
iance of expression level attributed by every technical and clinical covariate using variance par-
tition to adjust a subset of covariates. ii) Perform differential expression (DE) analysis to derive
significant DE genes/proteins/metabolites between groups of interest. iii) Build WGCNA co-
expression networks to select a set of modules enriched for significant functions. iv) Extract a
list of seeding genes from the selected modules and expand this seeding gene set by prior cell
type-specific signaling pathways built separately through pathFinder.
Key driver analysis (KDA) and prioritization of top hits
The fundamental idea of KDA algorithm is to search for master regulators upstream of a set of
user-defined downstream effector genes (in our study, we used the genes from the selected
modules and the DE genes) given a causal network structure based on Fisher´s exact test.
KDA, was performed using a modified version of the R package KDA [26] that we have pub-
lished in https://github.com/zhukuixi/KDA. Specifically, first a background sub-network is
defined by KDA by looking for a K-step upstream neighborhood round each node in the target
gene list in the network. Second, starting from each node in this sub-network, KDA evaluates
the enrichment of downstream neighborhoods (for each step size from 1 to K) for the target
gene list. K = 6 was used in this paper. This cutoff was chosen based on practical considerations
(K will depend on the size and complexity of the network) and while we can use other cut-offs,
K = 6 is commonly used in previous studies and is the default value suggested in the KDA soft-
ware [9,26,83,84]. This K value is preferred because the key drivers within K steps can all be
detected. However, as we learned from our knockdown experiment and Fig 6, when K gets too
large, the impact of a gene on the downstream genes diminishes exponentially. Therefore, we
believe that K = 6 is a reasonable choice for this study. Finally, we took the overlap of key driv-
ers identified from the AS and ApP networks and further ranked the top 9 KDs (described in
the results section and on Table 1).
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pathFinder, a fast graphical algorithm
pathFinder is a graphical algorithm we developed and described in [9]. The purpose of path-
Finder is to extract neighborhood structures, specifically to expand an initial set from a larger
background network. In particular for this paper we expanded the gene set arising from the
selected modules.
HMGCR inhibition in iPSC lines
iPSCs from 6 IS and 6 IR individuals were used in this validation experiment. These 6 individ-
uals were chosen based on the extremes of the distribution for insulin sensitivity and to reduce
the confounding genetic noise that intermediate samples could generate. We selected individu-
als with an SSPG over 200 for the IR group and individuals with an SSPG below 100 for the IS
group). In addition, we selected these samples in order to be able to match gender, age and
BMI between IR and IS samples. Full covariate information for these individuals can be found
in S5 Table. The cells were maintained in feeder-free conditions using mTesr1 (Stem Cell
technologies, Inc) supplemented with 1 mM L-Glutamine, 1mM Penicillin-Streptomycin,
0.1 μg/ml Fungizone.) on 5% matrigel coated 6-well TC plates. For passaging, cells were
washed once with PBS and treated with pre-warmed 1 mM EDTA (Sigma), incubated at 37
degrees for 1–5 minutes, and resuspended in fresh mTesr1 medium 2 μM Thiazovivin (Milli-
pore). After 12 hours incubation in Thiazovivin, medium was changed daily with fresh
mTesr1. Cells were grown to ~90–100% confluency, washed once with PBS and were treated
with either DMSO (D) or 1 uM Atorvastatin (A) (Selleckhem) for 12h. Cells were washed once
in PBS and harvested for RNA extraction using PureLInk RNA mini kit (Thermo Fisher Scien-
tific). Total RNA was quantified using a Nanodrop (Thermo Scientific). RNA samples with a
A260/280 ratio <1.8 or >2.3 were excluded from further processing and the RNA was
sequenced using the Illumina HiSeq 2500 system.
Cell culture
Simpson-Golabi-Behmel syndrome (SGBS) cells (human preadipocytes) were provided by Dr.
Martin Wabitsch (Ulm University, Ulm, Germany). SGBS cells were cultured in DMEM/F12
supplemented with 10% FBS, 33uM biotin, and 17uM panthotenate. The SKMC line HMCL-
7304 was provided by Institute of Child Health (ICH), University College London. Cells were
cultured in SKMC growth medium (PromoCell). iPSCs were generated and cultured as previ-
ously described [9].
Adipogenic and skeletal muscle differentiation
For adipogenic differentiation SGBS cells were grown to confluency and subjected to a two-
step differentiation process. Cells were first exposed for 3 days to media composed of DMEM/
F12 supplemented with 0.01mg/mL of transferrin, 20uM of insulin, 100nM cortisol, 0.2nM
3,30,5-Triiodo-L-thyronine, 25nM dexamethasone, 250uM 3-Isobutyl-1-methylaxanthine, and
2uM rosiglitazone. Afterwards, cells were exposed to DMEM/F12 supplemented with 0.01mg/
mL of transferrin, 20uM of insulin, 100nM cortisol, and 0.2nM 3,30,5-Triiodo-L-thyronine for
additional 12 days. HMCL-7304 cells were differentiated in presence of SKMC differentiation
medium (PromoCell) for 4–5 days before glucose uptake was performed.
For quantification of the effect on adipogenic differentiation, chemical inhibitors for
HMGCR (atorvastatin), FDPS (alendronate), and SQLE (terbinafine) were added at day 0 of
differentiation at different concentrations (10nM, 100nM, 1uM, 10uM.). Differentiation quan-
tification was performed with Oil Red O. Differentiated SGBS cells were fixed with 10%
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formalin for 10 minutes at room temperature. After washing with 60% isopropanol, samples
were incubated in Oil Red O (Sigma-Aldrich) for 10 minutes at rom temperature. Oil Red O
was eluted with 100% isopropanol for 10 minutes. The solution was then transferred into a
96-well plate and absorbance measured at 500nm.
Glucose uptake
Differentiated SGBS or HMCL-7304 cells cells were pretreated for 24 hours with different con-
centrations (10nM, 100nM, 1uM, 10uM) of the chemical inhibitors for HMGCR (atorva-
statin), FDPS (alendronate), and SQLE (terbinafine). After the preincubation, the cells were
starved for 2 hours prior to 30 minute of 100nM insulin stimulation at 37 degrees. Following
stimulation, cells were incubated with Krebs-Ringer bicarbonate-HEPES (KRBH) buffer
(130mM NaCl, 5mM KCl, 1.3mM CaCl2, 1.3 mM MgSO4, 25mM HEPES, pH 7.4) containing
100uM 2-deoxy-D-glucose, and 1uCi/ml 2-deoxy-D-[1,2-3H]glucose for 10 minutes at room
temperature. The cells were then washed with PBS, harvested in 300uL of M-PER lysis buffer
(ThermoFisher), and then added to scintillation vials containing 4.75mL of scintillation fluid
(Perk Elmer). Radioactive counts were determined with a scintillation counter (Model ID:
Beckman LS6500). Excess samples were subjected to BCA assay for protein quantification and
normalization of radioactive counts. All samples were represented as fold change compared to
the unstimulated (no insulin) condition.
Growth assay
SGBS or HMCL-7304 cells were plated at 50 or 100 cells/cm2 in 12 well plates and were grown
for 12 to 14 days in the absence or presence of 10nM, 100nM, 1uM, 10uM of atorvastatin, ter-
binafine or alendronate. After the treatment, the cells were fixed in cold methanol for 15 min-
utes and stained with crystal violet for 10 minutes. Dye excess was washed with water and
pictures taken immediately afterwards.
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S1 Fig. Reprogramming efficiency and SSPG distribution.
(TIF)
S2 Fig. Variance partition.
(TIF)
S3 Fig. Hierarchical clustering of samples.
(TIF)
S4 Fig. Significance of gene-pair correlation in the four co-expression networks.
(TIF)
S5 Fig. ApP subnetworks for the top 9 KDs.
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S6 Fig. Module annotation for the genes in the four subnetworks.
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S7 Fig. AS network validation.
(TIF)
S8 Fig. Cholesterol biosynthetic pathway and location of HMGCR, FDPS and SQLE.
(TIF)
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